Switch On Your HIV Smarts.

Video: Three PrEP Myths Busted

, by Florie Charles and Alex Olson

PrEP, short for pre-exposure prophylaxis, is a relatively new HIV prevention strategy in which an HIV-negative person takes a daily pill to reduce the risk for HIV infection.

PrEP has made headlines recently—and the messages haven’t always been clear. Watch this video to get the facts about how PrEP works and see three PrEP myths busted.

Florie Charles, a PhD candidate at the University of California, San Francisco, launched Youreka Science with the goal of making science more accessible to the public. Florie has recently been joined by Alex Olson in her endeavor to explain novel scientific findings and global health issues to improve health and raise awareness of the importance of biomedical research.

Have more questions about PrEP? Start here for basic PrEP facts and key terms, and check out BETA’s “virtual library” on PrEP. Stay tuned as we bring you more personal stories, articles, and other PrEP resources all month long!


11 Responses to Video: Three PrEP Myths Busted

  1. Samir Hussain says:

    please suggest.

  2. San Francisco AIDS Foundation says:

    Hi Samir. Thanks for your question. You might want to ask your provider for an RNA test, which detects genetic material from the virus. You and your provider need to rule out HIV infection before you can start PrEP. Also, keep in mind that PEP–post-exposure prophylaxis–must be started within 72 hours of a known or suspected exposure to HIV. Please take a look at our PrEP and PEP fact sheet to learn more: http://betablog.org/fact-sheet-prep-pep/.

  3. NATHAN says:

    I think it is misleading to state short term side effects are minor and that is the end of the story, any medicine, in fact anything you put in your body has long term effects on your health and physiology. It bothers me terribly that pro-prep people never seem to mention that we have almost no idea what years of taking these medications do to you, especially when widened to a more genetically diverse general population vs. a small study group.

  4. Pingback: PrEP’s Unexpected Gifts: A Q&A with Adam Zeboski

  5. Tom Craig says:

    I work with an AIDS group here in Paris, and I was wondering if it would be possible for us to do a French version of theis video? How can we get permission to do that please?
    Thanks in advance

  6. Pingback: Pedal for the Living - The Edge of the American West - The Chronicle of Higher Education

  7. Jeff says:

    First point -Nice idea shame about the drug. I have loss of bone density, fanconi syndrome and continuing kidney problems because of tenofovir a component of Truvada. These “rare” side effects are far more common than anyone will admit. With say 100,000 HIV positive people in the UK I should not know 5 people with fanconi’s which only affects 1 in 100,000 who is lying here? Anyone taking this drug should have kidney function checked monthly as fanconi’s can develop very fast. Second Point. A recent study shows that people are not taking the pill everyday – adherence is below 100% this risks creating resistant HIV strains to a medication which for all it’s faults is still a first line choice because most people tolerate it well.

  8. Pingback: Getting Comfortable with PrEP: A Provider’s Perspective

  9. Pingback: Webinar: Prescribing, Managing, and Billing for PrEP

  10. Pingback: What’s Next for PrEP? A Q&A with Dr. Susan Buchbinder

  11. Pingback: New Resource: Mapping Pathways U.S. Workshop Report